Cargando…
Bias with respect to socioeconomic status: A closer look at zip code matching in a pneumococcal vaccine effectiveness study
In 2010, 13-valent pneumococcal conjugate vaccine (PCV13) was introduced in the US for prevention of invasive pneumococcal disease in children. Individual-level socioeconomic status (SES) is a potential confounder of the estimated effectiveness of PCV13 and is often controlled for in observational s...
Autores principales: | Link-Gelles, Ruth, Westreich, Daniel, Aiello, Allison E., Shang, Nong, Weber, David J., Holtzman, Corinne, Scherzinger, Karen, Reingold, Arthur, Schaffner, William, Harrison, Lee H., Rosen, Jennifer B., Petit, Susan, Farley, Monica, Thomas, Ann, Eason, Jeffrey, Wigen, Christine, Barnes, Meghan, Thomas, Ola, Zansky, Shelley, Beall, Bernard, Whitney, Cynthia G., Moore, Matthew R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5033249/ https://www.ncbi.nlm.nih.gov/pubmed/27668279 http://dx.doi.org/10.1016/j.ssmph.2016.08.005 |
Ejemplares similares
-
Generalisability of vaccine effectiveness estimates: an analysis of cases included in a postlicensure evaluation of 13-valent pneumococcal conjugate vaccine in the USA
por: Link-Gelles, Ruth, et al.
Publicado: (2017) -
Direct and Indirect Impact of 13-valent Pneumococcal Conjugate Vaccine (PCV13) on Invasive Pneumococcal Disease (IPD) Among Children and Adults in the U.S.
por: Pilishvili, Tamara, et al.
Publicado: (2017) -
1470. Epidemiology of Invasive Pneumococcal Disease (IPD) Following 18 years of Pneumococcal Conjugate Vaccine (PCV) Use in the United States
por: Pilishvili, Tamara, et al.
Publicado: (2020) -
1436. Risk Factors for Invasive Pneumococcal Disease in Adults ≥65 Years Old Following Pneumococcal Conjugate Vaccine Recommendation
por: Almendares, Olivia M, et al.
Publicado: (2018) -
151. Evaluation of Pneumococcal Vaccine Effectiveness Against Invasive Pneumococcal Disease Among US Medicare Beneficiaries ≥65 Years Old
por: Pilishvili, Tamara, et al.
Publicado: (2018)